SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Recursion Presents Phase 2 REC-4881 Data Showing Polyp Reductions in FAP

Recursion Pharmaceuticals said Phase 2 REC-4881 data presented at CGA-IGC showed deep, durable polyp burden reductions in FAP.

RXRX

Related stories